INOVIO (NASDAQ: INO) announced execution of an agreement with Kaneka Corporation affiliate, Kaneka Eurogentec S.A. for the company to manufacture INOVIO’s coronavirus vaccine candidate INO-4800. Kaneka Eurogentec has joined existing partners Richter-Helm BioLogics, Ology Biosciences and Thermo Fisher Scientific in INOVIO’s global manufacturing consortium. Each contract has been chosen to join the consortium and may support INOVIO’s future global manufacturing needs across its array of DNA medicines and vaccines. INOVIO’s President & CEO, Dr. J. Joseph Kim, said, “Our partnership with Kaneka Eurogentec, one of the world’s largest and most experienced plasmid manufacturers, provides additional scale to our growing global manufacturing coalition. Kaneka Eurogentec will be a crucial member of INOVIO’s global manufacturing consortium, supporting our plans to produce, manufacture and scale our COVID-19 vaccine candidate, INO-4800.”
Dr. Lieven Janssens, Kaneka Eurogentec’s President and CEO, said, “We are excited to join INOVIO’s growing global manufacturing consortium and look forward to supporting the manufacturing needs of DNA medicines and vaccines across INOVIO’s platform. We are pleased that our large-scale manufacturing technologies are well-recognized by INOVIO, a leading player in the DNA plasmid field.”
INOVIO’s Senior Vice President of Biological Manufacturing and Clinical Supply Management, Robert J. Juba Jr., said, “Kaneka Eurogentec brings a wealth of DNA plasmid manufacturing expertise and innovation to INOVIO’s global consortium to manufacture INO-4800. We look forward to working with them to utilize their state-of-the-art, large-scale manufacturing capabilities towards our goal of producing hundreds of millions of doses of INO-4800 for worldwide distribution.”
Bagikan Berita Ini
0 Response to "INOVIO Executes Agreement with Kaneka Eurogentec S.A. to Manufacture COVID-19 Vaccine Candidate INO-4800 - Financialbuzz.com"
Post a Comment